Neuropace Current Deferred Revenue from 2010 to 2025
| NPCE Stock | USD 12.38 0.34 2.67% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 555 K | Current Value 527.2 K | Quarterly Volatility 2.9 M |
Check Neuropace financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuropace's main balance sheet or income statement drivers, such as Interest Income of 1.5 M, Depreciation And Amortization of 1.6 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 3.87, Dividend Yield of 0.0 or PTB Ratio of 42.71. Neuropace financial statements analysis is a perfect complement when working with Neuropace Valuation or Volatility modules.
Neuropace | Current Deferred Revenue |
Latest Neuropace's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Neuropace over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Neuropace's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuropace's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Neuropace Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 4,544,516 | |
| Geometric Mean | 3,114,507 | |
| Coefficient Of Variation | 64.13 | |
| Mean Deviation | 2,728,105 | |
| Median | 6,727,000 | |
| Standard Deviation | 2,914,581 | |
| Sample Variance | 8.5T | |
| Range | 6.2M | |
| R-Value | (0.85) | |
| Mean Square Error | 2.5T | |
| R-Squared | 0.72 | |
| Significance | 0.000031 | |
| Slope | (520,024) | |
| Total Sum of Squares | 127.4T |
Neuropace Current Deferred Revenue History
About Neuropace Financial Statements
Neuropace stakeholders use historical fundamental indicators, such as Neuropace's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Neuropace investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neuropace's assets and liabilities are reflected in the revenues and expenses on Neuropace's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neuropace. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 555 K | 527.2 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Neuropace Correlation against competitors. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 0.192 | Return On Assets | Return On Equity |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.